The addition of TUC increased the anti-tumor effects on metabolic activity, proliferation, and clonogenic survival, particularly in HER2-overexpressing BC cells, compared to irradiation alone; however, in contrast to the data shown for trastuzumab or lapatinib, no radiosensitizing effect was found [17, 18]. Here, ERBB2 is linked to breast cancer.